Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 215-237-7 | CAS number: 1314-60-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Direct observations: clinical cases, poisoning incidents and other
Administrative data
- Endpoint:
- direct observations: clinical cases, poisoning incidents and other
- Type of information:
- other: human data
- Adequacy of study:
- weight of evidence
- Study period:
- January 1994 - December 1996
- Reliability:
- other: high
- Rationale for reliability incl. deficiencies:
- other: The publication has a high reliability. Comment: Very detailed description of responses and adverse effects.
Data source
Reference
- Reference Type:
- publication
- Title:
- Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral lesihmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.
- Author:
- Thakur, C.P. et al.
- Year:
- 1 998
- Bibliographic source:
- Annals of Tropical Medicine & parasitology, 92 (5): 561 - 569.
Materials and methods
- Study type:
- clinical case study
- Endpoint addressed:
- not applicable
Test guideline
- Qualifier:
- no guideline required
- Principles of method if other than guideline:
- Eighty parasitologically confirmed cases of visceral leishmaniasis (kala-azar) in Bihar, India, were treated daily with 20 mg sodium stibogluconate/kg for 30 days, to assess the current efficacy and toxicity of this 30-day regimen. The test substance was administered intramuscular.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- sodium stibogluconate (SSG)
- IUPAC Name:
- sodium stibogluconate (SSG)
- Details on test material:
- - Name of test material (as cited in study report): Sodium stibogluconate (SSG)
No further information on the test material was stated.
Constituent 1
Method
- Type of population:
- general
- Subjects:
- - Number of subjects exposed: 80 patients
- Sex: 67 males / 13 females
- Age: 6-10 years: 17 patients (21%); 11-20 years: 17 patients (21%); 21 -30 years: 18 patients (23 %); 31 -40 years: 15 patients (19%); 41 - 50 years: 10 patients (13%); 51 - 60 patients: 3 patients (4%)
- Race: the race was not stated.
The study was conducted in Patna medical College Hospital and Balaji Utthan Sansthan, both in Patna, Bihar, India. Patients with visceral leishmaniasis (VL; kala-azar) (confirmed by demonstration of amastigotes in Giemsa-stained smears of splenic aspirates) were admitted to the study if : they had no history of treatment with any antileishmanial drug; the y were between 6 and 60 years old; they had no serious concurrent illness (such as HIV infection, tuberculosis, pneumonia, or cardiac, renal or hepatic disease); and they were not pregnant. informed consent to participate was obtained and the study was cleared by the local ethical committee. - Ethical approval:
- confirmed and informed consent free of coercion received
- Route of exposure:
- other: intramuscular injection
- Reason of exposure:
- intentional
- Exposure assessment:
- measured
- Details on exposure:
- See "Medical treatment" below
- Examinations:
- Initial assessment of those enrolled included the following:
- Urine analysis
- Haematological testing: Counts of leucocytes and platelets, estimation of prothrombin time and haemoglobin concentration
- Biochemical testing: Serum concentration of sodium, potassium, creatinine, asparate and aniline aminotransferase, and albumin.
- Physical exammination: Measurement of spleen and liver size and body weight
- Other: Electrocardiograms (ECG) and chest X-rays
Appropriate investigations were repeated at the end of treatment (day 30) and at follow-up (days 60, 90, 120, 150 and 180).
The spleen of each patient was aspirated on days 0, 30 and 180. the aspirates were stained with Giemsa and checked for amistigotes, independently, by two experienced parasitologists.
Clinical cure was defined as absence of fever and reduction in the size of spleen at the end of treatment, parasitological cure as absence of parasites in splenic aspirates recovered at the end of treatment, and ultimate cure as the absence of clinical or parasitological relapse within 6 months of initiating treatment.Patients were followed monthly for 6 months.
Intercurrent infections were treated as appropriate. Unresponsive patients, relapsing patients, and patients who were withdran from the study were treated with amphotericin B deoxycholate, administered at a dose of 1 mg/kg.day for 20 days.
Adverse events were monitored daily. - Medical treatment:
- Each patient was given an intramuscular injection of SSG, at a dose of 20 mg/kg body weight (to a maximum daily dose of 850 mg), daily for 30 days, in one of both buttocks.
Results and discussion
- Clinical signs:
- In the study the patients that were admitted to the study showed as the main presenting features intermittent fever, shivering, and diminution in appitite. Several patients had clinical features of malnutrition (hair loss in 11 patients, leg oedema in five, angular stomatitis in two).
The 30-day regimen of SSG commonly caused adverse effects. There was considerable evidence of gastro-intestinal toxicity. Severe loss of appetite (i.e. complete aversion to food) occurred in one patient, who was withdrawn from the study on day 24. His liver, pancreatic and renal functions were within normal limits. He was parasitologically positive at the time of withdrawal, started having fever 3 weeks later and was then treted with amphotericin B and cured.
Furthermore, minor side effects of sodium stibogluconate were pain at the site of injection (2 patients), mild diminution in appetite (12 patients) metallic taste in mouth (6 patients), and joint pain (2 patients). - Results of examinations:
- - Urine analysis: no data
- Haematological examination: In the study the patients that were admitted to the study showed as the main presenting features anaemia (all patients) and leucopenia. At the end of treatment (day 30) and throughout follow-up, the mean leucocyte count and haemoglobin concentration were all significantly higher.
- Biochemical examination: In patients that were admitted to the study, the mean concentration of serum albumin (3.0g/dl) was less than the normal range(3.6 - 4.7 g/dl). At the end of treatment (day 30) and throughout follow-up, the serum albumin concentration was significantly higher. There were no significant changes in the concentrations of serum creatinine, asparate aminotransferase, alanine aminotransferase, sodium or potassium, or blood urea at the end of treatment.
- Physical examination: In the study the patients that were admitted to the study showed as the main presenting features loss of weight and splenohepatomegaly. Every patient complained of weight loss. At the end of treatment the mean spleen and liver sizes were significantly smaller than pre-treatment (day 0).
- Electrocardiograms and chest X-rays: The 30-day regimen of SSG commonly caused adverse effects. Electrocardiographic changes occurred in many of the patients, diminution in the height of the T wave in 32 (40 %) patients, inversion of the T wave in 7 (9 %), elevation of the ST segment in 3 (4 %), prolonged QT interval in 6 (8 %) and diminution in the height of P, R and T waves in 2 (3 %). Cardiac arrhythmia occurred in 5 (6 %) patients, supraventricular arrhythmia in one and ventricular tachycardia, ventricular fibrillation, torsade de pointes and multifocal ventricular ecotopics occurred in the 4 patients who died. - Effectivity of medical treatment:
- In this case the test substance is the medical treatment. For effectiveness see "Outcome of incidence" below.
- Outcome of incidence:
- The 30-day regimen of SSG failed in 34 (46%) of the patients.
Curing rate: Clinical and parasitological cure was obtained for 48 (60 %) patients, however 26 (33 %) patients did not respond to the first course of treatment.
Applicant's summary and conclusion
- Conclusions:
- Curing rate:
Clinical and parasitological cure was obtained for 48 (60 %) patients, however 26 (33 %) patients did not respond to the first course of treatment.
Adverse effects:
Electrocardiographic changes occurred in many of the patients, diminution in the height of the T wave in 32 (40 %) patients, inversion of the T wave in 7 (9 %), elevation of the ST segment in 3 (4 %), prolonged QT interval in 6 (8 %) and diminution in the height of P, R and T waves in 2 (3 %). Cardiac arrhythmia occurred in 5 (6 %) patients, supraventricular arrhythmia in one and ventricular tachycardia, ventricular fibrillation, torsade de pointes and multifocal ventricular ecotopics occurred in the 4 patients who died. Minor side effects were pain at the site of injection (2), mild diminution in appetite (12) metallic taste in mouth (6), and joint pain (2).
Tentative LOAEL:
not assignable
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.